Growth, Trends, and Opportunities in the Roxadustat Market: Key Insights for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Long-Term Projected Growth Rate for the Roxadustat Market, and What Are the Key Drivers?
In recent years, the market size of Roxadustat has seen considerable growth. The market, which amounts to $6.44 billion in 2024, is projected to expand to $6.92 billion in 2025, showing a compound annual growth rate (CAGR) of 7.5%. This growth during the historic period can be credited to regulatory clearances in key markets, impressive results from clinical trials, a rise in the number of chronic kidney disease cases, increased knowledge about anemia management, and governmental backing for anemia therapies.
In the ensuing years, the Roxadustat market is set to witness robust growth. It is anticipated to reach $9.16 billion by 2029, boasting a compound annual growth rate (CAGR) of 7.3%. The growth during this forecast period can be credited to ongoing investigations for novel indications, elevated healthcare expenses, a need for non-injectable anemia treatments, broadening reimbursement policies, and an aging global population. Key trends for the forecast period encompass a shift toward oral anemia therapies, intensified competition from alternative treatments, the proliferation of licensing agreements, increased funding for hypoxia-inducible factor research, and an emphasis on patient-focused treatment modalities.
How Are the key drivers Contributing to the Expansion of the Roxadustat Market?
The surge in the prevalence of chronic kidney disease (CKD) is anticipated to foster the expansion of the Roxadustat market. Chronic kidney disease (CKD) is a progressive condition, characterized by the steady loss of kidney functionality, eventually leading to kidney failure if neglected. The global spike in the number of people suffering from chronic kidney disease is attributed to an ageing population, escalating rates of ailments such as diabetes, hypertension and overall unhealthy living habits. Roxadustat assists in handling chronic kidney disease by promoting erythropoietin production, leading to an increase in the creation of red blood cells, tackling anemia often linked with the disease, thereby enhancing total kidney operation and life quality for those inflicted. For example, in December 2024, a report revealed by the Australian Institute of Health and Welfare (AIHW), a government agency based in Australia, showcased that mortality figures for chronic kidney disease witnessed a slight yearly increase, surging by 4.2% in 2021 and 6.2% in 2022. Hence, the escalating number of individuals afflicted with chronic kidney disease (CKD) is propelling the growth of the Roxadustat market.
Get Your Free Sample of the Global Roxadustat Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp
Which Companies Are Leading the Charge in Expanding the Roxadustat Market?
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.
What New Trends Are Reshaping the Roxadustat Market and Its Opportunities?
Key businesses in the Roxadustat market are pursuing reimbursement through the high-tech drugs scheme, eliminating financial hindrances to expand patient accessibility, speeding up market absorption, and showcasing their innovative treatments’ cost-effectiveness. The high-tech drugs scheme is a government initiative predominantly in Ireland that offers financial coverage for the prescription of costly, highly specialized medicines often prescribed in hospitals. For example, in September 2022, Astellas Pharma Company Ltd., a U.S.-based pharmaceutical company, revealed that its EVRENZO (Roxadustat) had received reimbursement under Ireland’s High-Tech Drugs Scheme. Roxadustat represents the first of a new category of orally taken inhibitors called hypoxia-inducible factor prolyl hydroxylase (HIF PH), which have been licensed and reimbursed in Ireland. The reports reveal that Roxadustat successfully attained and maintained the target haemoglobin levels (10-12g/dL) in patients suffering from symptomatic anemia of CKD, regardless of their dialysis status and previous ESA treatment.
Get Instant Access to the Global Roxadustat Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report
What Major Market Segments Define the Scope and Growth of the Roxadustat Market?
The roxadustat market covered in this report is segmented –
1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions
Subsegments:
1) By 20mg: Oral Tablets, Injectable Formulations
2) By 50mg: Oral Tablets, Injectable Formulations
What Are the Top Regions Fueling Growth in the Roxadustat Market?
North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Roxadustat Market Defined Across Different Regions?
Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, leading to increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without the need for exogenous erythropoiesis-stimulating agents. It is used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production.
Browse Through More Similar Reports By The Business Research Company:
Meningococcal Vaccines Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report
Nontuberculous Mycobacterial Infection Global Market Report 2025
Multidrug Resistant Bacteria Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
